|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results provide the first detailed mechanism of how the AR can differentially alter PCa and BCa metastasis; thus, targeting the newly identified AR-miR-525-5p-SLPI axis may help suppress metastasis.
|
31843555 |
2020 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these results suggest that androgens may not only function via the classic nAR to increase the nAR-positive BCa cell invasion, they may also function via this newly identified mAR-SLC39A9 to increase the nAR-negative/mAR-positive BCa cell invasion.
|
31506605 |
2020 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Additionally, overexpression of AR suppressed ENZ-induced autophagy-related genes (LC3-II/I, ATG5, and p-AMPKα) in T24 cells, and CQ exerted synergistic effects with ENZ to suppressed AR-responsive genes expression (KLK2 and KLK3) in bladder cancer.
|
31574376 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
|
31234917 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We indicate that AR plays an essential role in bladder cancer progression in male patients.
|
31119584 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accordingly, the investigation of lncRNAs is improving our understanding of genitourinary cancers, from development to progression and dissemination. lncRNAs are involved in major oncogenic events in genitourinary malignancies, including androgen receptor (AR) signalling in prostate cancer, hypoxia-inducible factor (HIF) pathway activation in renal cell carcinoma and invasiveness in bladder cancer, as well as multiple other proliferation and survival mechanisms.
|
31110275 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to delineate the role of AR signaling in BCa and to determine whether the combination of AR inhibitor, Enzalutamide (Enz), and Cisplatin (Cis) efficiently inhibit the growth of BCa cells.
|
31006613 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
As androgen receptor (AR) reportedly affects bladder cancer, we assessed the correlation between NMIBC recurrence and tumor AR expression in Japanese patients.
|
30961575 |
2019 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
|
30864720 |
2019 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In order to evaluate the potential prognostic/predictive role of androgen receptor (AR) expression in non-muscle-invasive bladder cancer (NMIBC), and whether it may represent a therapeutic target, we conducted a systematic search of the literature using 'androgen receptor or AR', 'testosterone', 'bladder cancer' and 'non-muscle invasive bladder cancer or NMIBC' as keywords.
|
31803932 |
2019 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Preclinical models have demonstrated that androgen receptor modulation can influence bladder carcinogenesis with an inverse association observed between serum androgen levels and bladder cancer (BC) incidence.
|
29731413 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen Receptor Is Inactivated and Degraded in Bladder Cancer Cells by Phenyl Glucosamine via miR-449a Restoration.
|
29659560 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study investigated the functional role of androgen-associated androgen receptor (AR) mediated-eRNA MARC1 (eMARC1) in BCa progression.
|
29964053 |
2018 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
NF-κB activators and inhibitors also significantly induced and reduced, respectively, cell proliferation/migration/invasion of AR-positive bladder cancer lines, but not AR-knockdown or AR-negative lines, and their growth in xenograft-bearing mice.
|
29592878 |
2018 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that AR activity inversely correlates with radiosensitivity in bladder cancer.
|
29720561 |
2018 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We therefore conducted this meta-analysis to assess the clinicopathological impact of the expression of androgen receptor (AR) and estrogen receptors (ERs) in bladder cancer.
|
28362839 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: We summarize and discuss available data suggesting the involvement of AR and its potential downstream targets in the development and progression of bladder cancer.
|
28064545 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given that the androgen receptor (AR) has been discussed as a possible factor in the development and progression of bladder cancer, we investigated the predictive value of AR in stage pT1 NMIBC.
|
28342317 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The correlations of miR-124 with XIST and AR in bladder cancer samples were statistically analyzed.
|
28869948 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, androgen-mediated androgen receptor signals have been shown to correlate with the promotion of tumor development and progression, which may clearly explain some sex-specific differences in bladder cancer.
|
28241422 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging preclinical evidence suggests the critical role of androgen-mediated androgen receptor (AR) signals in the development of bladder cancer.
|
29119053 |
2017 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that enzalutamide may have the potential to treat patients with advanced gemcitabine-resistant bladder cancer with increased AR expression.
|
27909718 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thiazolyl blue cell viability assay, flow cytometry, scratch wound-healing assay, transwell invasion assay, real-time polymerase chain reaction, and reporter gene assay were performed in AR-positive (e.g., UMUC3, TCCSUP, and 647V-AR) and AR-negative (e.g., UMUC3-AR-short hairpin RNA [shRNA], TCCSUP-AR-shRNA, 647V) bladder cancer lines treated with dihydrotestosterone and each AR antagonist.
|
27330033 |
2016 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice.
|
26862755 |
2016 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, in vivo mouse models of xenografted bladder cancer T24 cells with CD4(+) T cells confirmed in vitro coculture studies and concluded that infiltrating CD4(+) T cells can promote bladder cancer metastasis via modulation of the IL1→AR→HIF1α→VEGFa signaling.
|
27196763 |
2016 |